Erika Hamilton, MD, FASCO· @ErikaHamilton9 · X·· 1 day agoScore70
Body
#FINER fulvestrant +/- ipatasertib (AKTi)
45% of pts were pathway altered
PFS lengthened in ITT HR 0.68
and AKT altered cohorts HR 0.55
93% diarrhea, pretty high G2/3 rates
#ESMO26 #ESMOAmbassadors
29 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgSource: Erika Hamilton, MD, FASCO · x.com